BioNTech SE - ADR

NASDAQ:BNTX  
133.90
+1.61 (+1.22%)
Products, Expansion

BioNTech Starts Construction Of First mRNA Vaccine Manufacturing Facility In Africa

Published: 06/23/2022 10:06 GMT
BioNTech SE - ADR (BNTX) - Biontech Starts Construction of First Mrna Vaccine Manufacturing Facility in Africa.
Delivery of First Container Modules Planned for End of 2022.
Facility Will Be Initially Equipped With Two Biontainers, and is Expected to Employ About 100 Staff by 2024.
Biontech's Malaria Vaccine Candidates to Enter First-in-human Trial Later in 2022.